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Abstract	  
In the vast sea of life sciences, the emergence of microfluidics and plasmon optics, like 
intrepid explorers, has enabled us to venture into uncharted territories. These fresh domains 
offer unprecedented possibilities in generating new quantitative biological understanding 
and precision medicine paradigms. Microfluidics and plasmon optics approaches empower 
detailed investigation at the molecular, sub-cellular, single-cell, and tissue network level. 
They also provide high-content molecular-level resolution and detail that is crucial for the 
advancement of precision medicine. These new insights and innovative inventions that 
offer superior solutions for life sciences research and precision healthcare have been made 
possible through the convergence of knowledge in biology, physical sciences, engineering, 
and medicine in the following areas: 
   
 
Single	  Cell	  Analysis	  	  
Pioneering work in microfluidics has enabled us to make new discoveries in the sea of 
cellular heterogeneity. Discerning cellular heterogeneity is important for understanding 
fundamental cellular processes and translational medicine research in the areas of aging, 
stem cells, and cancer. To overcome the technical limitations associated with single-cell 
culture and measurements, dynamic single cell analysis platforms were created by our 
group to distinguish cellular heterogeneity [1-5]. 
A higher resolution two-stage system to define cellular heterogeneity was also recently 
described by us [6]. In the first stage, multiplexed single-cell RNA cytometry was 
performed in microwell arrays containing over 60,000 reaction chambers. In the second 
stage, RNA cytometry data was used to determine cellular heterogeneity by defining a 
likelihood score. Monte-Carlo simulation and RNA cytometry data enabled calculation of 
the minimum number of cells required for detecting cellular heterogeneity. This 
experimental paradigm was applied to characterize RNA distributions of ageing-related 
genes in a highly purified mouse haematopoietic stem cell population. A novel group of 
genes that contributed to cellular heterogeneity was identified with this approach. It was 
also established that changes in the expression of certain genes like Birc6 during cellular 
ageing were attributable to a shift in relative cell proportions in high-expressing subgroups 
versus low-expressing subgroups. Microfluidic single cell analysis platforms have 
prompted new approaches for studies in ageing, stem cell biology, and cancer cell biology. 
Concurrent transcript and protein quantification is conceptually appealing because of the 
potential to elucidate cryptic properties of biological systems that are not accurately 
represented by either mRNA or protein analysis alone. For applications in cancer, a 
microwell-based cytometric method was developed for simultaneous measurements of gene 
and protein expression dynamics in thousands of single cells [7]. The regulatory effects of 
transcriptional and translational inhibitors of cMET mRNA and protein in cell populations 
were quantified. Next, the dynamic responses of individual cells to drug treatments were 
studied by measuring cMET overexpression in individual non-small cell lung cancer 
(NSCLC) cells with induced drug resistance. Distinct correlated transcript– protein 
signatures emerged across NSCLC cell lines with a specified protein expression profile. 
This platform is ideal for interrogating the dynamics of gene expression, protein 
expression, and translational kinetics at the single-cell level, and represents a paradigm 
shift towards discovering vital cell regulatory mechanisms. 
Microphysiological	  Analysis	  Platforms	  (MAPs)	  	  
Integrated microfluidics systems are a key component of MAPs that provide clear 
navigation through the turbulent waters of drug discovery. MAPs are physiologically 
relevant dynamic 3D cell culture microfluidic systems and artificial organ models on-chip 
[8-11]. The first artificial liver sinusoid model on-chip described was instrumental in 
starting a scientific movement immersed in developing organ on-chip platforms [11]. 
Improved patient and disease-specific iPSC- based organ on-chip platforms for 
personalized medicine research are currently being developed [12]. 
Drug discovery and development are hampered by high failure rates attributed to an 
overreliance on non-human animal models for safety and efficacy testing. A fundamental 
problem inherent in this approach is that non-human animal models are not adequately 
representative of human biology. Consequently, there is an urgent need for high-content in 
   
 
vitro systems that accurately recapitulate physiological microenvironments and predict 
drug-induced toxicity reliably. Organ systems, which predict cardiotoxicity, are of principal 
importance because approximately one third of safety-based pharmaceutical withdrawals 
are due to cardiotoxicity issues. 
A cardiac MAP with the characteristics of an ideal in vitro system for predicting 
cardiotoxicity was recently described [12]. Salient features of this cardiac MAP platform 
include cells with a human genetic background, physiologically relevant tissue architecture 
(e.g. aligned cells), computationally predictable perfusion mimicking human vasculature, 
and multiple modes of analysis (e.g. biological, electrophysiological, and physiological). 
The cardiac MAP can keep human induced pluripotent stem cell derived cardiac tissue 
viable and functional over extended periods. Pharmacological studies using the cardiac 
MAP platform showed half maximal inhibitory/effective concentration values (IC50/EC50) 
that are consistent with tissue and cellular scale reference data. MAPs are being adopted for 
human disease modeling, drug development, and toxicology. Currently, mini-brain MAP 
and pancreatic islet MAP devices are also being researched. 
Optofluidics	  for	  Application	  Specific	  Integrated	  Systems	  (OASIS)	  	  
Explorations in the realm of light-controlled microfluidics or optofluidics has led to the 
creation of sensitive and specific OASIS technologies for molecular diagnostics. The rapid 
diagnosis of infectious and human diseases requires an integrated molecular diagnostic 
platform with specific sample preparation units coupled to fast and sensitive detection 
methods for DNA, RNA, and protein biomarkers. Several, stand-alone, self-powered, and 
integrated microfluidic blood analysis platforms were established for the advancement of 
low-cost molecular diagnostic healthcare systems [13-19]. A handheld point-of-care 
genomic diagnostic system fulfilling the requirements and infrastructural limitations in 
resource poor settings and for use both developing and developed countries was recently 
described by us [15]. 
In the domain of label-free detection, integrated optofluidics has helped advance single 
molecular level surface enhanced Raman spectroscopy and nanoplasmonic PCR 
technologies. Improvements in PCR nucleic acid amplification and quantification are 
important because PCR remains the most sensitive, powerful, and widely used diagnostic 
tool in existence. In order to address problems associated with conventional PCR thermal 
cyclers, such as, fast cycling speed, uniform heating and cooling, and large heating block 
mass, an innovative optofluidic cavity PCR method using light- emitting diodes was 
developed [20, 21]. Ultrafast photonic PCR technology is based on plasmonic photothermal 
light-to-heat conversion via photon–electron–phonon coupling. An efficient photonic heat 
converter was designed and constructed using a thin Au film due to plasmon-assisted high  
optical  absorption  features  of  Au  film.  The plasmon-excited Au film is capable of 
rapidly heating the surrounding solution. Using this method, ultrafast thermal cycling (30 
cycles) from 55 oC for annealing to 95 oC for denaturation can be accomplished within 5 
min. This simple, robust and low cost approach to ultrafast PCR with efficient photonic-
based heating can be readily integrated into a variety of devices or methods, including on-
chip thermal lysis for sample preparation and heating for isothermal amplification. This 
optofluidic cavity PCR is highly desirable for rapid and accurate molecular diagnostics and 
precision medicine applications. An integrated OASIS platform with different sample 
preparation units will contribute to transformative life sciences experimental methodologies 
and molecular diagnostics. These concepts will be especially important for the 
   
 
development of lightweight, point-of- care devices for use in both developing and 
developed countries. 
The life sciences are a vast sea, yet optofluidics has guided and empowered us to 
explore previously uncharted waters. This knowledge base has become a widely 
sought-after companion when venturing into new realms of science and technology. 
New holistic systems and improved adaptive and scalable experimental strategies for 
precision medicine can be derived from optofluidics while inspirations from biology 
can guide us in the design and development of these technologies [22-25]. 
Collectively, these strategies will provide unparalleled ability to perform experiments 
which were once ethically and technically unfeasible. Overall, the fundamental 
knowledge gained from this research can be readily translated into new technologies, 
theranostics, treatment paradigms, and personalized medicine solutions to improve the 
quality of life globally. 
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